Chimeric Antigen Receptor News and Research

RSS

Genetically engineered T cells can target, attack pathogenic T cells that cause Type 1 diabetes

A new study has found that a novel T cell genetically engineered by University of Arizona Health Sciences researchers is able to target and attack pathogenic T cells that cause Type 1 diabetes, which could lead to new immunotherapy treatments.

3 Dec 2020

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.

1 Dec 2020

Penn study opens the door to let CAR T cells reach the tumor microenvironment

The labyrinth of jumbled blood vessels in the tumor microenvironment remains one of the toughest blockades for cellular therapies to penetrate and treat solid tumors.

30 Nov 2020

Combining cell engineering with machine learning to design living medicines for cancer

Finding medicines that can kill cancer cells while leaving normal tissue unscathed is a Holy Grail of oncology research.

26 Nov 2020

Novel CAR T-cell therapy shows promising early results in children with neuroblastoma

A novel CAR T-cell therapy developed by researchers at UCL and designed to target cancerous tumors, has shown promising early results in children with neuroblastoma, a rare form of childhood cancer.

25 Nov 2020

A new method to improve the preclinical evaluation of CAR T cell therapies

Ludwig Cancer Research scientists have developed a method to significantly improve the preclinical evaluation of chimeric antigen-receptor (CAR) T cell therapies, in which the immune system's T cells are extracted from a patient, engineered to target a specific tumor-associated molecule and then grown and reinfused for cancer treatment.

6 Nov 2020

Radiation therapy before CART-BCMA appears to be a safe option for multiple myeloma patients

Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy, according to a new study from researchers in the Abramson Cancer Center at the University of Pennsylvania to be presented Tuesday, October 27, at the virtual American Society for Radiation Oncology Annual Meeting (Abstract #35562).

27 Oct 2020

Novel microfluidic approach to fight cancer could greatly benefit patients

CAR-T biotherapeutics company Carina Biotech and researchers at the University of South Australia have developed a novel approach based on microfluidic technology to "purify" the immune cells of patients in the fight against cancer.

20 Oct 2020

A strategic collaboration to speed up the development of allogeneic cell therapies

The University of Texas MD Anderson Cancer Center and Allogene Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the preclinical and clinical investigation of AlloCAR T candidates across Allogene's broad portfolio of hematologic and solid tumors.

16 Oct 2020

Cancer-killing T cells release chemicals to direct swarms towards tumors

When immune system T cells find and recognise a target, they release chemicals to attract more T cells which then swarm to help subdue the threat, shows a new study published today in eLife.

13 Oct 2020

CAR NKT cells offer a promising approach to combat hard-to-treat solid tumors

Natural killer T (NKT) cells, a type of immune cells known for their potent anti-cancer properties in murine tumor models, have been developed into a novel form of immunotherapy to treat patients with cancer.

13 Oct 2020

FDA awards six clinical trial research grants to enhance development of therapies for rare diseases

Today, the U.S. Food and Drug Administration announced that it has awarded six new clinical trial research grants to principal investigators from academia and industry totaling over $16 million over the next four years.

8 Oct 2020

A global review of COVID-19 impact on cancer treatment and research

The COVID-19 pandemic has impacted virtually every aspect of cancer care and research- from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research, a review of scientific literature shows.

7 Oct 2020

Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

The U.S. Food and Drug Administration has granted Fast Track designation to a novel "switchable" CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process.

1 Oct 2020

Researchers decipher how the immune system memorizes pathogens after an infection

The immune system will memorize the pathogen after an infection and can therefore react promptly after reinfection with the same pathogen. Now, scientists at the University of Würzburg have deciphered new details of this process.

28 Sep 2020

Challenges in High Complexity Flow Cytometry

In this interview, Dra. Mª José Marco from the Department of Hematology at Hopsital Dr. Peset talks to News-Medical Life Sciences about high complexity flow cytometry and the challenges they often face.

From Beckman Coulter Life Sciences - Flow Cytometry 24 Sep 2020

NCCN's first patient and caregiver resource focused on childhood leukemia

The National Comprehensive Cancer Network today announced the publication of the organization's first patient and caregiver resource focused on a childhood cancer type.

23 Sep 2020

Research uncovers potential cause of neurotoxicity due to immunotherapy

New research has uncovered the previously unknown presence of CD19 -- a B cell molecule targeted by chimeric antigen receptor (CAR) T cell immunotherapy to treat leukemia, lymphoma, and multiple myeloma -- in brain cells that protect the blood brain barrier (BBB).

21 Sep 2020

Drug used in rheumatoid arthritis and cancer treatment improves survival in critically ill COVID-19 patients

Researchers at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network, have utilized its statewide observational database of more than 5,000 hospitalized COVID-19 patients to show that a drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically-ill patients admitted to the intensive care unit (ICU).

20 Aug 2020

Researchers identify drug that improves survival in critically ill COVID-19 patients

19 Aug 2020